What is electroCore?
electroCore is at the forefront of bioelectronic medicine, specializing in a non-invasive vagus nerve stimulation platform designed to treat a range of neurological disorders. The company's therapeutic approach initially targets conditions such as cluster headache, migraine, and episodic cluster headache, with indications extending to adolescents and adults for acute and preventive treatments. By leveraging technology to modulate nerve activity, electroCore aims to provide effective, drug-free treatment options, positioning itself as a key innovator in the medtech sector.
How much funding has electroCore raised?
electroCore has raised a total of $227.4M across 7 funding rounds:
Series A
$50M
Debt
$1.5M
Series B
$70M
Stock Offering
$78M
Share Placement
$25M
Debt
$1M
Private Equity
$1.9M
Series A (2014): $50M with participation from Easton Capital, Merck Global Health Innovation Fund, and Core Ventures Group
Debt (2016): $1.5M, investors not publicly disclosed
Series B (2017): $70M supported by Gakasa, The Vinik Family Foundation, American Investment Holdings LLC, Merck Global Health Innovation Fund, and Core Ventures Group
Stock Issuance/Offering (2018): $78M, investors not publicly disclosed
Share Placement (2020): $25M backed by Lincoln Park Capital Fund , LLC
Debt (2020): $1M with participation from PPP
Private Equity (2025): $1.9M, investors not publicly disclosed
Key Investors in electroCore
Easton Capital
Easton Capital Investment Group is a venture capital firm that manages approximately $200 million across three funds, specializing in investments ranging from $2 million to $7.5 million and possessing strategic co-investment capabilities for larger funding rounds.
Merck Global Health Innovation Fund
Merck Global Health Innovation Fund, associated with the global healthcare company Merck & Co., Inc., invests in innovative solutions within the healthcare sector, including prescription medicines, biologic therapies, vaccines, and animal health products.
Core Ventures Group
Core Ventures Group is a venture capital firm founded in 2012 that focuses on supporting entrepreneurs by investing in seed-stage companies with proven business models and advanced technologies, leveraging their entrepreneurial experience and networks.
What's next for electroCore?
With the recent influx of capital, electroCore is poised for significant expansion. The company's strategic investment, particularly in the context of its overall funding trajectory, suggests a move towards scaling commercial operations and potentially broadening its therapeutic indications. Future developments are likely to focus on increasing market access for its existing product lines and advancing its research and development pipeline. The company's ability to attract substantial backing from established investors highlights confidence in its technology and its potential to disrupt traditional treatment paradigms in neurology.
See full electroCore company page
